Monthly Archives: February 2015

 

Submissions Open for Biotechnica Award

Submissions are now open for the EUROPEAN BIOTECHNICA AWARD. The coveted award will go to a European company that has introduced a disruptive technology in the field of biotechnology or the life sciences and has demonstrably shepherded it through to successful commercialization. The EUROPEAN BIOTECHNICA AWARD is offered by Deutsche...
Read more

Gamida Cell Orphan Status for Transplants

Gamida Cell, a developer of cell therapy technologies and products for transplantation and adaptive immune therapy, announced that orphan drug designation has been granted by the FDA for its investigational medicinal product NiCord. The drug is used for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin...
Read more

EarlySense Raises $20 M

Ramat Gan-based EarlySense, which provides solutions for contact-free patient monitoring, announced today that it has completed a $20 million financing round, led by Samsung Ventures with an investment of $10 million. Existing investors whose participation was also substantial include Pitango Venture Capital, Welch Allyn, JK&B, Proseed and Noaber. “We are...
Read more

Drug & Med Device Regulatory Course

Sarah Furie, a veteran specialist in the field of drug and medical device regulation and registration, is offering a course on the subject in collaboration with Tel Aviv University starting March 8. For more info tadan1@netvision.net.il...
Read more

cCam Phase I for Cancer

cCAM Biotherapeutics has started a Phase 1 trial assessing the effect of the CM-24 mAb on cancer patients with advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal and ovarian cancers. The main objectives of the study are to assess the safety and tolerability of CM-24 and to...
Read more

D-Pharm Raises 12.8 M NIS

D-Pharm Ltd (TASE: DPRM) has raised 12.8M NIS in aggregate. D-Pharm’s largest shareholder, CLAL Biotechnology (CBI), exercised all its rights to the tune of 8.7M NIS and a third of the total funds raised were from the public. D-Pharm is a clinical-stage neuroscience company focused on the development of pioneering...
Read more

Pluristem BMT Pre-Clinical Success

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PSTI) has shown strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation. In the study, conducted in conjunction with Hadassah Medical Center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy, mice with damaged bone marrow who...
Read more